{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T18:07:47Z","timestamp":1714586867976},"reference-count":39,"publisher":"Consilium Medicum","issue":"8","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir\/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods. The study enrolled adult patients with HCV genotype 1b infection without demonstrated NS5A resistance - associated substitutions Y93C\/H\/N\/S and\/or L31F\/M\/V\/I. Patients were treated with narlaprevir 200 mg QD, ritonavir 100 mg QD and daclatasvir 60 mg QD. Treatment duration was 12 weeks. Proportion of patients achieving sustained virological response 12 weeks after treatment (SVR12) was the primary efficacy endpoint. Results and discussion. In total, 105 (75.0%) patients were treatment with the study combination. Patients\u2019 age varied from 21 to 69 years, the mean age being 43.2\u00b110.9 years. There were slightly more women (55.2%), and 69 patients (65.7%) had comorbidities. SVR 12 was 89.5% (95% CI 82.0-94.7%). In 10 of 11 patients with treatment failures NS5A resistance - associated substitutions in residues 31 and\/or 93 were found, as well as less clinically relevant substitutions L28M, P58S, R30Q, Q62K. Adverse events (AEs) were found in less than one half of patients (45 patients, or 42.9% in the safety population). Almost all recorded AEs were mild to moderate. Conclusion. Efficacy of treatment with a combination of narlaprevir\/ritonavir and daclatasvir in treatment - na\u00efve patients with HCV genotype 1b was close to 90%. This combination was found to be safe and well - tolerated.<\/jats:p>","DOI":"10.26442\/00403660.2019.08.000384","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T21:59:22Z","timestamp":1567893562000},"page":"67-74","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of narlaprevir\/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C"],"prefix":"10.26442","volume":"91","author":[{"given":"E A","family":"Klimova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E Z","family":"Burnevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V P","family":"Chulanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O O","family":"Znoyko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S N","family":"Batskikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S N","family":"Kizlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N A","family":"Mamonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E P","family":"Tarkhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E N","family":"Krasavina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Yu","family":"Samsonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N D","family":"Yushchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"ref1","unstructured":"World Health Organization 2017, Global hepatitis report, 2017 Publication date: April 2017 Languages: English ISBN: 978-92-4-156545-5"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.012"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"ref4","unstructured":"WHO International Agency for Research on Cancer, editor. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100: A review of human carcinogens. Part B: Biological agents. Lyon, 2012."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32277-3"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.20953\/17299225201833745"},{"key":"ref8","unstructured":"\u042e\u0449\u0443\u043a \u041d.\u0414., \u0417\u0430\u0439\u0440\u0430\u0442\u044c\u044f\u043d\u0446 \u041e.\u0412., \u0417\u043d\u043e\u0439\u043a\u043e \u041e.\u041e., \u0425\u0440\u0438\u043f\u0443\u043d \u0410.\u0418., \u0414\u0443\u0434\u0438\u043d\u0430 \u041a.\u0420., \u0413\u0443\u0434\u043a\u043e\u0432\u0430 \u0421.\u0411., \u041a\u043b\u0438\u043c\u043e\u0432\u0430 \u0415.\u0410., \u041a\u0440\u0430\u0441\u043d\u0435\u043d\u043a\u043e\u0432\u0430 \u0421.\u0424., \u0416\u0443\u0440\u0430\u0432\u043b\u0435\u0432\u0430 \u0410.\u0412., \u041e\u0440\u0435\u0445\u043e\u0432 \u041e.\u041e., \u0411\u0435\u043b\u044b\u0439 \u041f.\u0410. \u0411\u0440\u0435\u043c\u044f \u0441\u043c\u0435\u0440\u0442\u043d\u043e\u0441\u0442\u0438 \u043e\u0442 \u0432\u0438\u0440\u0443\u0441\u043d\u044b\u0445 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u043e\u0432 \u0412 \u0438 \u0421: \u043c\u0435\u0442\u043e\u0434\u043e\u043b\u043e\u0433\u0438\u044f \u043e\u0446\u0435\u043d\u043a\u0438 \u0438 \u043f\u043e\u043a\u0430\u0437\u0430\u0442\u0435\u043b\u0438 \u0432 \u041c\u043e\u0441\u043a\u0432\u0435 \u0432 2015-2017 \u0433\u0433. \u0418\u043d\u0444\u0435\u043a\u0446\u0438\u043e\u043d\u043d\u044b\u0435 \u0431\u043e\u043b\u0435\u0437\u043d\u0438: \u043d\u043e\u0432\u043e\u0441\u0442\u0438, \u043c\u043d\u0435\u043d\u0438\u044f, \u043e\u0431\u0443\u0447\u0435\u043d\u0438\u0435. 2018;7(4):8-14."},{"key":"ref9","unstructured":"\u042e\u0449\u0443\u043a \u041d.\u0414., \u0417\u043d\u043e\u0439\u043a\u043e \u041e.\u041e., \u042f\u043a\u0443\u0448\u0435\u0447\u043a\u0438\u043d\u0430 \u041d.\u0410., \u0417\u044b\u0440\u044f\u043d\u043e\u0432 \u0421.\u041a., \u0428\u0443\u0442\u044c\u043a\u043e \u0421.\u0410., \u0411\u0435\u043b\u044b\u0439 \u041f.\u0410. \u0438 \u0434\u0440. \u0411\u0440\u0435\u043c\u044f \u0432\u0438\u0440\u0443\u0441\u043d\u044b\u0445 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u043e\u0432 \u0432 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u0438 \u043f\u0443\u0442\u0438 \u0435\u0433\u043e \u0441\u043d\u0438\u0436\u0435\u043d\u0438\u044f \u0432 \u0434\u043e\u043b\u0433\u043e\u0441\u0440\u043e\u0447\u043d\u043e\u0439 \u043f\u0435\u0440\u0441\u043f\u0435\u043a\u0442\u0438\u0432\u0435 (\u043d\u0430 \u043f\u0440\u0438\u043c\u0435\u0440\u0435 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421). \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2013;85(12):79-85."},{"key":"ref10","unstructured":"\u042e\u0449\u0443\u043a \u041d.\u0414., \u0417\u043d\u043e\u0439\u043a\u043e \u041e.\u041e., \u042f\u043a\u0443\u0448\u0435\u0447\u043a\u0438\u043d\u0430 \u041d.\u0410. \u0438 \u0434\u0440. \u041e\u0446\u0435\u043d\u043a\u0430 \u0441\u043e\u0446\u0438\u0430\u043b\u044c\u043d\u043e - \u044d\u043a\u043e\u043d\u043e\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0431\u0440\u0435\u043c\u0435\u043d\u0438 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421 \u0432 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438. \u042d\u043f\u0438\u0434\u0435\u043c\u0438\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0432\u0430\u043a\u0446\u0438\u043d\u043e\u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0430. 2013;2(69):18-33."},{"key":"ref11","unstructured":"\u041d\u0438\u043a\u0438\u0442\u0438\u043d \u0418., \u041f\u043e\u043f\u043e\u0432\u0438\u0447 \u041b.\u0414., \u041f\u043e\u0442\u0430\u043f\u0447\u0438\u043a \u0415.\u0413. \u041e\u0446\u0435\u043d\u043a\u0430 \u044d\u043a\u043e\u043d\u043e\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0431\u0440\u0435\u043c\u0435\u043d\u0438 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421 \u0432 \u0420\u0424 \u042d\u043f\u0438\u0434\u0435\u043c\u0438\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u043e\u043d\u043d\u044b\u0435 \u0431\u043e\u043b\u0435\u0437\u043d\u0438. \u0410\u043a\u0442\u0443\u0430\u043b\u044c\u043d\u044b\u0435 \u0432\u043e\u043f\u0440\u043e\u0441\u044b. 2015;(6):9-13."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12351"},{"key":"ref13","unstructured":"WHO Global health sector strategy on viral hepatitis 2016-2021. WHO\/HIV\/2016.06 Available from: http:\/\/www.who.int\/hepatitis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref15","unstructured":"\u0418\u0432\u0430\u0448\u043a\u0438\u043d \u0412.\u0422., \u042e\u0449\u0443\u043a \u041d.\u0414., \u0440\u0435\u0434\u0430\u043a\u0442\u043e\u0440\u044b. \u0420\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u0432\u0437\u0440\u043e\u0441\u043b\u044b\u0445 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u043e\u043c \u0421. \u041c.: \u0413\u042d\u041e\u0422\u0410\u0420-\u041c\u0435\u0434\u0438\u0430, 2017."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.24411\/2305-3496-2018-14001"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23899"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00135-10"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1021\/ml9000276"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(09)60088-X"},{"key":"ref21","unstructured":"Vierling J.M, Poordad F.F, Lawitz E, Ghalib R.H, Lee W.M, Ravendhran N, Galati G.S, Bacon B.R, Flamm S.L, Balart L.A, Freilich B, Schiff E.R, Jacobson I.M, Kwo P.Y, Gordon S.C, Sulkowski M.S, Jiang R, Boparai N, Chaudhri E.I, Treitel M.A, Hughes E.A, Brass C.A, Albrecht J.K. Once daily Narlaprevir (NVR; SCH 900518) and Ritonavir (RTV) in combination with peginterferon alfa-2b\/ribavirin (PR) for 12 weeks plus 12 weeks PR in treatment - naive patients with HCV genotype 1 (G1): SVR results from NEXT-1, a phase 2 study. Hepatology. 2011;54:1437A."},{"key":"ref22","unstructured":"Abdurakhmanov D.T, Bakulin I.G, Bogomolov P.O et al. Final results from a phase III study of the Narlaprevir, a novel Russian protease inhibitor in treatment - naive and previously treated patients with genotype 1 chronic hepatitis C (the PIONEER trial). Hepatol Int. 2017;11(Suppl.):S305-6."},{"key":"ref23","unstructured":"\u0411\u0443\u0440\u043d\u0435\u0432\u0438\u0447 \u042d.\u0417., \u0422\u0438\u0445\u043e\u043d\u043e\u0432\u0430 \u041d.\u042e., \u0429\u0430\u043d\u0438\u0446\u0438\u043d\u0430 \u0421.\u0415. \u041d\u0430\u0440\u043b\u0430\u043f\u0440\u0435\u0432\u0438\u0440, \u0431\u0443\u0441\u0442\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u0439 \u0440\u0438\u0442\u043e\u043d\u0430\u0432\u0438\u0440\u043e\u043c, \u0432 \u043a\u043e\u043c\u0431\u0438\u043d\u0430\u0446\u0438\u0438 \u0441 \u043f\u0435\u0433\u0438\u043b\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u043c \u0438\u043d\u0442\u0435\u0440\u0444\u0435\u0440\u043e\u043d\u043e\u043c - \u03b1 \u0438 \u0440\u0438\u0431\u0430\u0432\u0438\u0440\u0438\u043d\u043e\u043c \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u044f. 2014;23(5):34-9."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01044-16"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.22416\/1382-4376-2017-27-6-41-51"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0221-5"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.024"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13376"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14096"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27972"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61793-1"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"ref33","unstructured":"\u0411\u0443\u0440\u043d\u0435\u0432\u0438\u0447 \u042d.\u0417., \u0413\u0443\u0441\u0435\u0432 \u0414.\u0410., \u0417\u043d\u043e\u0439\u043a\u043e \u041e.\u041e., \u041a\u043b\u0438\u043c\u043e\u0432\u0430 \u0415.\u0410., \u0427\u0443\u043b\u0430\u043d\u043e\u0432 \u0412.\u041f., \u0411\u0430\u0446\u043a\u0438\u0445 \u0421.\u041d., \u041a\u0438\u0436\u043b\u043e \u0421.\u041d., \u041c\u0430\u043c\u043e\u043d\u043e\u0432\u0430 \u041d.\u0410., \u0422\u0430\u0440\u0445\u043e\u0432\u0430 \u0415.\u041f., \u041a\u0440\u0430\u0441\u0430\u0432\u0438\u043d\u0430 \u042d.\u041d., \u0421\u0430\u043c\u0441\u043e\u043d\u043e\u0432 \u041c.\u042e., \u042e\u0449\u0443\u043a \u041d.\u0414. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0438 \u0431\u0435\u0437\u043e\u043f\u0430\u0441\u043d\u043e\u0441\u0442\u044c \u043d\u0430\u0440\u043b\u0430\u043f\u0440\u0435\u0432\u0438\u0440\u0430\/\u0440\u0438\u0442\u043e\u043d\u0430\u0432\u0438\u0440\u0430 \u0432 \u043a\u043e\u043c\u0431\u0438\u043d\u0430\u0446\u0438\u0438 \u0441 \u0434\u0430\u043a\u043b\u0430\u0442\u0430\u0441\u0432\u0438\u0440\u043e\u043c \u0443 \u0440\u0430\u043d\u0435\u0435 \u043d\u0435 \u043f\u043e\u043b\u0443\u0447\u0430\u0432\u0448\u0438\u0445 \u043f\u0440\u043e\u0442\u0438\u0432\u043e\u0432\u0438\u0440\u0443\u0441\u043d\u0443\u044e \u0442\u0435\u0440\u0430\u043f\u0438\u044e \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u043e\u043c \u0421 \u0431\u0435\u0437 \u0446\u0438\u0440\u0440\u043e\u0437\u0430 \u043f\u0435\u0447\u0435\u043d\u0438, \u0438\u043d\u0444\u0438\u0446\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u0445 \u0432\u0438\u0440\u0443\u0441\u043e\u043c \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u0430 \u0421 \u0433\u0435\u043d\u043e\u0442\u0438\u043f\u0430 1b. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u044f. 2018;27(4)."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09936-5"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i12.1617"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"ref38","unstructured":"Sarpel D, Wasserman I, Trochtenberg A, et al. Non - adherence is the most important risk factor for ledipasvir\/sofosbuvir HCV treatment failure in the real world Reported by Jules Levin AASLD 2016. Available from: http:\/\/www.natap.org\/2016\/AASLD\/AASLD_75.htm"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.11.007"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33621\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33621\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:33:51Z","timestamp":1634160831000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2019.08.000384","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,15]]}}}